Limiting Access to Abortion Pill Would Drive Up Costs for Employers

Recent court battles over an abortion drug could result in higher health care costs for employers and higher rates of absences related to pregnancy and childbirth.
On Aug. 16, the 5th U.S. Circuit Court of Appeals concluded that mifepristone should maintain its approval from the U.S. Food and Drug Administration (FDA), but the federal government should reverse its regulatory changes made in recent years.
Source: New feed 2